Advertisement

Coinfection with Hepatitis B or C in People Living with HIV Undergoing Immunosuppressive Therapy

  • Stefan K. BartaEmail author
Chapter

Abstract

HIV and both the hepatitis B virus (HBV) and hepatitis C virus (HCV) share similar forms of transmission (unprotected sexual intercourse, injection drug use (IDU), and transfusion of blood products), which explains why coinfection with HIV and either HBV, HCV, or even both is not uncommon. Additionally, patients coinfected with HIV and hepatitis B or C are at a higher risk of decompensation of liver disease and development of cirrhosis [1–5]. Therefore, screening of all patients diagnosed with HIV for hepatitis infection is critical to identify coinfection and prevent excess morbidity and mortality.

Keywords

Toxicity Hepatitis Albumin Europe Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgement

I would like to thank Dr. Minhhuyen T. Nguyen for critically reviewing this chapter.

References

  1. 1.
    Deng LP, Gui XE, Zhang YX, et al. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. World J Gastroenterol. 2009;15:996–1003.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet. 2000;356:1800–5.CrossRefPubMedGoogle Scholar
  4. 4.
    Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:593–601.CrossRefPubMedGoogle Scholar
  5. 5.
    Nikolopoulos GK, Paraskevis D, Hatzitheodorou E, et al. Impact of hepatitis B virus infection on the progression of AIDS and mortality in HIV-infected individuals: a cohort study and meta-analysis. Clin Infect Dis. 2009;48:1763–71.CrossRefPubMedGoogle Scholar
  6. 6.
    Price H, Bansi L, Sabin CA, et al. Hepatitis B virus infection in HIV-positive individuals in the UK collaborative HIV cohort (UK CHIC) study. PLoS One. 2012;7:e49314.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Pittman C, Plitt S, Birse T, et al. Prevalence and correlates of HIV and hepatitis B virus coinfection in Northern Alberta. Can J Infect Dis Med Microbiol. 2014;25:e8–13.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Spradling PR, Richardson JT, Buchacz K, et al. Prevalence of chronic hepatitis B virus infection among patients in the HIV Outpatient Study, 1996–2007. J Viral Hepat. 2010;17:879–86.CrossRefPubMedGoogle Scholar
  9. 9.
    Morsica G, Ancarani F, Bagaglio S, et al. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection. 2009;37:445–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Coffin CS, Mulrooney-Cousins PM, Osiowy C, et al. Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy. J Clin Virol. 2014;60:347–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Maldonado-Rodriguez A, Cevallos AM, Rojas-Montes O, et al. Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: a review of prevalence, diagnosis and clinical significance. World J Hepatol. 2015;7:253–60.PubMedCentralCrossRefPubMedGoogle Scholar
  12. 12.
    Chadwick D, Doyle T, Ellis S, et al. Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: a point prevalence study. HIV Med. 2014;15:189–92.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Petty LA, Steinbeck JL, Pursell K, et al. Human immunodeficiency virus and coinfection with hepatitis B and C. Infect Dis Clin N Am. 2014;28:477–99.CrossRefGoogle Scholar
  14. 14.
    Marcellin F, Lorente N, Demoulin B, et al. Comparison of risk factors in HIV-infected men who have sex with men, coinfected or not with hepatitis C virus (ANRS VESPA2 French cross-sectional national survey). Sex Transm Infect. 2015;91:21–3.CrossRefPubMedGoogle Scholar
  15. 15.
    Kouyos RD, Rauch A, Braun DL, et al. Higher risk of incident hepatitis C virus coinfection among men who have sex with men, in whom the HIV genetic bottleneck at transmission was wide. J Infect Dis. 2014;210:1555–61.CrossRefPubMedGoogle Scholar
  16. 16.
    Akselrod H, Grau LE, Barbour R, et al. Seroprevalence of HIV, hepatitis B virus, and HCV among injection drug users in Connecticut: understanding infection and coinfection risks in a nonurban population. Am J Public Health. 2014;104:1713–21.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Sanchez MA, Scheer S, Shallow S, et al. Epidemiology of the viral hepatitis-HIV syndemic in San Francisco: a collaborative surveillance approach. Public Health Rep. 2014;129 Suppl 1:95–101.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Serrano-Villar S, Sobrino-Vegas P, Monge S, et al. Decreasing prevalence of HCV coinfection in all risk groups for HIV infection between 2004 and 2011 in Spain. J Viral Hepat. 2015;22:496–503.CrossRefPubMedGoogle Scholar
  19. 19.
    Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:221–44.e3.CrossRefPubMedGoogle Scholar
  20. 20.
    Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–43.CrossRefPubMedGoogle Scholar
  22. 22.
    Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Leaw SJ, Yen CJ, Huang WT, et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83:270–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Huang H, Li X, Zhu J, et al. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA. 2014;312:2521–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhong S, Yeo W, Schroder C, et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat. 2004;11:55–9.CrossRefPubMedGoogle Scholar
  26. 26.
    Di Bisceglie AM, Lok AS, Martin P, et al. Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703–11.CrossRefPubMedGoogle Scholar
  27. 27.
    Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306–11.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer. 2006;106:1320–5.CrossRefPubMedGoogle Scholar
  29. 29.
    Rossi G, Pelizzari A, Motta M, et al. Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol. 2001;115:58–62.CrossRefPubMedGoogle Scholar
  30. 30.
    Yeo W, Chan PK, Ho WM, et al. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol. 2004;22:927–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998;339:61–8.CrossRefPubMedGoogle Scholar
  32. 32.
    Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003;125:1714–22.CrossRefPubMedGoogle Scholar
  33. 33.
    Benhamou Y, Tubiana R, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med. 2003;348:177–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis. 2004;189:1185–92.CrossRefPubMedGoogle Scholar
  35. 35.
    Boyd A, Lasnier E, Molina JM, et al. Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use. Antivir Ther. 2010;15:963–74.CrossRefPubMedGoogle Scholar
  36. 36.
    Martin-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Wilkins E, Nelson M, Agarwal K, et al. British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Med. 2013;14 Suppl 4:1–71.Google Scholar
  38. 38.
    Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–2.CrossRefPubMedGoogle Scholar
  39. 39.
    Reddy KR, Beavers KL, Hammond SP, et al. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–9; quiz e16–7.CrossRefPubMedGoogle Scholar
  40. 40.
    Mahale P, Kontoyiannis DP, Chemaly RF, et al. Acute exacerbation and reactivation of chronic hepatitis C virus infection in cancer patients. J Hepatol. 2012;57:1177–85.CrossRefPubMedGoogle Scholar
  41. 41.
    Markovic S, Drozina G, Vovk M, et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology. 1999;46:2925–30.PubMedGoogle Scholar
  42. 42.
    Kawatani T, Suou T, Tajima F, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol. 2001;67:45–50.CrossRefPubMedGoogle Scholar
  43. 43.
    Faggioli P, De Paschale M, Tocci A, et al. Acute hepatic toxicity during cyclic chemotherapy in non Hodgkin’s lymphoma. Haematologica. 1997;82:38–42.PubMedGoogle Scholar
  44. 44.
    Takai S, Tsurumi H, Ando K, et al. Prevalence of hepatitis B and C virus infection in haematological malignancies and liver injury following chemotherapy. Eur J Haematol. 2005;74:158–65.CrossRefPubMedGoogle Scholar
  45. 45.
    Zuckerman E, Zuckerman T, Douer D, et al. Liver dysfunction in patients infected with hepatitis C virus undergoing chemotherapy for hematologic malignancies. Cancer. 1998;83:1224–30.CrossRefPubMedGoogle Scholar
  46. 46.
    Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol. 2012;9:156–66.CrossRefPubMedGoogle Scholar
  47. 47.
    Zaky AH, Bakry R, El-Sayed MI, et al. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Hematology. 2014;19:412–6.CrossRefPubMedGoogle Scholar
  48. 48.
    Merli M, Visco C, Spina M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99:489–96.PubMedCentralCrossRefPubMedGoogle Scholar
  49. 49.
    Visco C, Arcaini L, Brusamolino E, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol. 2006;17:1434–40.CrossRefPubMedGoogle Scholar
  50. 50.
    Ennishi D, Maeda Y, Niitsu N, et al. Hepatic toxicity and prognosis in hepatitis C virus–infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis. Blood. 2010;116:5119–25.CrossRefPubMedGoogle Scholar
  51. 51.
    Sridharan A, Curtis SA, Kaner JD, et al. Hepatitis C co-infection in HIV-positive patients treated for lymphoma. ASCO Meet Abstr. 2014;32:8578.Google Scholar
  52. 52.
    Besson C, Canioni D, Lepage E, et al. Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus–positive patients in LNH 93 and LNH 98 Groupe d’Etude des Lymphomes de l’Adulte Programs. J Clin Oncol. 2006;24:953–60.CrossRefPubMedGoogle Scholar
  53. 53.
    European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2014. J Hepatol. 2014;61:373–95.CrossRefGoogle Scholar
  54. 54.
    Miller MH, Agarwal K, Austin A, et al. Review article: 2014 UK consensus guidelines – hepatitis C management and direct-acting anti-viral therapy. Aliment Pharmacol Ther. 2014;39:1363–75.CrossRefPubMedGoogle Scholar
  55. 55.
    WHO Guidelines Approved by the Guidelines Review Committee. Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014. Copyright (c) World Health Organization 2014.Google Scholar
  56. 56.
    Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313(12):1223–31.CrossRefPubMedGoogle Scholar
  57. 57.
    Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Graham CS. Hepatitis C and HIV: closing the gaps. JAMA. 2015;313:1217–8.Google Scholar
  59. 59.
    Hull M, Klein M, Shafran S, et al. CIHR Canadian HIV trials network coinfection and concurrent diseases core: Canadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults. Can J Infect Dis Med Microbiol. 2013;24:217–38.PubMedCentralPubMedGoogle Scholar
  60. 60.
    European AIDS Clinical Society (EACS) guidelines. 22 Apr 2015. http://www.eacsociety.org/files/guidelines-7.1-english.pdf.
  61. 61.
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 22 Apr 2015. http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
  62. 62.
    Ghany MG, Nelson DR, Strader DB, et al. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54:1433–44.PubMedCentralCrossRefPubMedGoogle Scholar
  63. 63.
    Hermine O, Lefrere F, Bronowicki JP, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med. 2002;347:89–94.CrossRefPubMedGoogle Scholar
  64. 64.
    Kelaidi C, Rollot F, Park S, et al. Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia. 2004;18:1711–6.CrossRefPubMedGoogle Scholar
  65. 65.
    Gisbert JP, Garcia-Buey L, Pajares JM, et al. Systematic review: regression of lymphoproliferative disorders after treatment for hepatitis C infection. Aliment Pharmacol Ther. 2005;21:653–62.CrossRefPubMedGoogle Scholar
  66. 66.
    Vallisa D, Bernuzzi P, Arcaini L, et al. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin’s lymphoma: a multicenter Italian experience. J Clin Oncol. 2005;23:468–73.CrossRefPubMedGoogle Scholar
  67. 67.
    La Mura V, De Renzo A, Perna F, et al. Antiviral therapy after complete response to chemotherapy could be efficacious in HCV-positive non-Hodgkin’s lymphoma. J Hepatol. 2008;49:557–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  1. 1.Fox Chase Cancer Center, Temple BMT ProgramTemple University Health SystemPhiladelphiaUSA

Personalised recommendations